DMAC stock information

Sector:

Healthcare

Description:

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics Inc. website

Current Price

$2.60

RSI

48.29

Market Capitalization:

31.5M

Beta:

1.993

Volume:

58,077

Analyst Target Price:

$ 10.67

Economiic Fair Price:

Earnings DateNovember 09, 2022

Report DateNovember 09, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash

Debt

EPS-0.594

Profit MarginN/A

Revenue Per Share TTM0

Return On Equity TTM-0.321

2018 Revenue

$ 500K

2021 Free Cash Flow

$ -12.3M

-32.95 %

2020 Free Cash Flow

$ -9.2M

-1.41 %

2019 Free Cash Flow

$ -9.1M

-58.44 %

2018 Free Cash Flow

$ -5.7M

-46.51 %

2017 Free Cash Flow

$ -3.9M

-29.44 %

2016 Free Cash Flow

$ -3M

2018 Pre Tax Income

$ -5.7M

DiaMedica Therapeutics Inc.(DMAC)